Tenofovir disoproxil fumarate (TDF)
Treatment for Acute Hepatitis B
Typical Dosage: 300 mg orally once daily
Effectiveness
80%
Safety Score
60%
Clinical Trials
3
Participants
500
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
300 mg orally once daily
Time to Effect
2-4 weeks for initial viral response, clinical improvement varies
Treatment Duration
Variable, typically 6-12 months post HBsAg seroconversion or longer in severe cases
Evidence Quality
MODERATEConfidence Score
75%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$480
Monitoring:$900
Side Effect Mgmt:$200
Total Annual:$1,580
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODQALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$2,107
Cost per Remission
$2,431
Tenofovir disoproxil fumarate (TDF) Outcomes
for Acute Hepatitis B
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+75%
Remission Rate
+65%
Common Side Effects
Nausea
+8%
Diarrhea
+6%
Headache
+5%
Abdominal pain
+5%
Renal impairment
+3%
Bone mineral density loss
+3%
Lactic acidosis (rare)
+0.1%
Sources:
Active Clinical Trials
1 active trial recruiting for Tenofovir disoproxil fumarate (TDF) in Acute Hepatitis B
Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF
NCT03920618RECRUITINGNA
150 participants
INTERVENTIONAL
Guangzhou, China
Started: Feb 21, 2019
Completed Clinical Trials
1 completed trial for Tenofovir disoproxil fumarate (TDF) in Acute Hepatitis B
Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver Failure
NCT01074645COMPLETEDPHASE4
27 participants
INTERVENTIONAL
New Delhi, India
Started: Nov 1, 2007